Silva-Rosales NA, Enrique TC, Cervantes-Kardasch VH, Del-Toro M

Language: Spanish
References: 18
Page: 97-103
PDF size: 270.06 Kb.

ABSTRACT

Background. Different patterns of heptavalent conjugated pneumococcal vaccine immunization have proven effective. Although three and four doses are recommended, there are still children who are administered schemes of two primary vaccination doses without reinforcement. The aim of this study was to compare the immune response against S. pneumoniae in children (group A and group B) submitted to different immunization schemes (two primary vaccination doses with or without reinforcement).
Methods. We conducted an observational, cross-sectional study comparing the immune response between group A and group B, analyzing the weak immune response with positive hemagglutination dilution ≤1:2. Odds ratio (OR) and Fisher's exact test were used.
Results. There were no clinical differences between group A (n = 14) and group B (n = 15). There was a higher proportion of weak immune response in group A (57% vs. 13%, OR 8.7 (95% CI 1.3–53.8, p = 0.017).
Conclusions. Weak immune response against S. pneumoniae is higher in schemes primed with two doses of heptavalent conjugated pneumococcal vaccine without reinforcement than using the two-dose schedule + a booster of heptavalent conjugated pneumococcal vaccine.

REFERENCES

1. Guevara M, Barricarte A, Pérez B, Arriazu M, García Cenoz M, Castilla J. La vacuna neumocócica conjugada heptavalente (Prevenar™). Diferencias en su efectividad en distintas poblaciones. An Sis Sanit Navar 2008;31:171-192.

2. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187-195.

3. Käyhty H, Åhman H, Eriksson K, Sörberg M, Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J 2005;24:108-114.

4. Dawson B, Trapp R. Basic and Clinical Biostatistics. USA: McGraw-Hill; 2006.

5. Vesta L, González A, Coronel DL, Aldama O, Gómez CM, Desentis JF, et al. Manual de vacunación 2008-2009. México, DF: Centro Nacional para la Salud de la Infancia y la Adolescencia; 2008.

6. Lee H, Nahm MH, Burton R, Kim KH. Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol 2009;16:376-381.

7. Abbas AK, Lichtman AH, Pillai S. Inmunología Celular y Molecular. Madrid: Elsevier; 2008.

8. Davidson M, Bulkow LR, Grabman J, Parkinson AJ, Chamblee C, Williams WW, et al. Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch Intern Med 1994;154:2209-2014.

9. Lockhart SP, Hackell JG, Fritzell B. Pneumococcal conjugate vaccines: emerging clinical information and its implications. Expert Rev Vaccines 2006;5:553-564.

10. Ruggeberg JU, Collins C, Clarke P, Johnson N, Sinha R, Everest N, et al. Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. Vaccine 2007;25:264-271.

11. Sánchez L, Pérez D, Alfonso L, Castro M, Sánchez LM, Van der Stuyft P, et al. A community education strategy to promote participation in dengue prevention in Cuba. Rev Panam Salud Publica 2008;24:61-69.

12. Instituto Nacional de Salud Pública. Encuesta Nacional de Cobertura del Esquema de Vacunación 2008.

13. Beltrán L. Comunicación para la salud del pueblo. Una revisión de conceptos básicos. Estudios sobre las Culturas Contemporáneas 2010;31:17-65.

14. Henry JB, Todd JC, Sanford AH, Davidsohn I. Diagnóstico y Tratamiento Clínicos por el Laboratorio. Barcelona: Salvat; 1988.

15. Kabat EA. Antibodies responsible for allergic reactions and the difficulties involved in studying them. Int Arch Allergy Appl Immunol 1961;18:1-2.

16. Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, Kida H, et al. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog 2009;5:e1000350.

17. Effler PV, Bogard AK, Domen HY, Katz AR, Higa HY, Sasaki DM. Evaluation of eight rapid screening tests for acute leptospirosis in Hawaii. J Clin Microbiol 2002;40:1464-1469.

18. Sanz JC, Culebras E, Ríos E, Rodríguez-Avial I, Wilhelmi I, Ramos B, et al. Direct serogrouping of Streptococcus pneumoniae strains in clinical samples by use of a latex agglutination test. J Clin Microbiol 2010;48:593-595. doi:10.1128/JCM.01651-09.